RxDoctor Payments Data

Alex Orten, MD

Psychiatry · Anchorage, AKNPI 1518912849

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $71,586 of the $116,172 with a category attached, or 61.6%. Neurocrine Biosciences, Inc. accounts for 99.8% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2022 at $42,688 and has fallen 78.2% since, to $9,291 in 2025. Among psychiatry clinicians in AK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$116,172in general payments, 2019–2025

Across 148 payments — averaging $784.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$116K
  • AbbVie$174
  • Teva Pharmaceuticals USA, Inc.$23
  • Otsuka America Pharmaceutical, Inc.$14

What the payments were for

  • Consulting fees$26,56023%
  • Speaking & faculty fees$71,58662%
  • Travel & lodging$13,86812%
  • Food & beverage$4,1584%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$116,172 in reported general payments places this provider in the 95th percentile of 81 psychiatry providers in Alaska.

See all psychiatry providers in Alaska

Medicare billing

Part B allowed, 2024
$14,322
Medicare patients
33
Services billed
172

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate23$42,913
VraylarCariprazine Hcl25$37,246
VivitrolNaltrexone Microspheres11$21,214
Clozapine53$5,709
Olanzapine171$5,548
Naltrexone Hcl70$1,366
Aripiprazole237$1,141
Divalproex Sodium ErDivalproex Sodium45$1,087
AmantadineAmantadine Hcl18$969
Olanzapine OdtOlanzapine54$678
Sertraline Hcl192$583
Quetiapine Fumarate103$572
Prazosin Hcl118$506
Propranolol Hcl ErPropranolol Hcl37$393
Buspirone Hcl28$392

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$174$37,24625 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 81 psychiatry providers in Alaska.

Other psychiatry in Anchorage

See the full list for Alaska

Where these figures come from

Is this you, or does something look wrong? →